Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C.

Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019.

2.

Groin Pain Syndrome Italian Consensus Conference on terminology, clinical evaluation and imaging assessment in groin pain in athlete.

Bisciotti GN, Volpi P, Zini R, Auci A, Aprato A, Belli A, Bellistri G, Benelli P, Bona S, Bonaiuti D, Carimati G, Canata GL, Cassaghi G, Cerulli S, Delle Rose G, Di Benedetto P, Di Marzo F, Di Pietto F, Felicioni L, Ferrario L, Foglia A, Galli M, Gervasi E, Gia L, Giammattei C, Guglielmi A, Marioni A, Moretti B, Niccolai R, Orgiani N, Pantalone A, Parra F, Quaglia A, Respizzi F, Ricciotti L, Pereira Ruiz MT, Russo A, Sebastiani E, Tancredi G, Tosi F, Vuckovic Z.

BMJ Open Sport Exerc Med. 2016 Nov 29;2(1):e000142. doi: 10.1136/bmjsem-2016-000142. eCollection 2016. Erratum in: BMJ Open Sport Exerc Med. 2017 Jan 3;2(1):e000142corr1.

3.

Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.

Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A.

World J Hepatol. 2016 Aug 8;8(22):949-56. doi: 10.4254/wjh.v8.i22.949.

4.

Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.

Marchetti A, Pace MV, Di Lorito A, Canarecci S, Felicioni L, D'Antuono T, Liberatore M, Filice G, Guetti L, Mucilli F, Buttitta F.

Lung Cancer. 2016 Sep;99:11-6. doi: 10.1016/j.lungcan.2016.06.005. Epub 2016 Jun 14.

PMID:
27565907
5.

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.

Marchetti A, Di Lorito A, Pace MV, Iezzi M, Felicioni L, D'Antuono T, Filice G, Guetti L, Mucilli F, Buttitta F.

J Thorac Oncol. 2016 Apr;11(4):487-95. doi: 10.1016/j.jtho.2015.12.111. Epub 2016 Feb 22.

6.

Abdominal Wall: Register & Miscellaneous.

Alves A, Gritsch K, Villle V, Drevon-Gaillotl E, Bayon Y, Clermont G, Boutrand JP, Grosgogea B, Cox T, Huntington C, Blair L, Prasad T, Augenstein V, Heniford BT, Lalán JG, Vázquez LL, Di Marzo F, Ipponi PL, Marioni A, Felicioni L, Pieralli F, Sergi A, Forni S, Darienzo S, Vannucci A, Reinpold W, Samartsev VA, Gavrilov VA, Parshakov AA, Chistyakova DM, Sidorenko AY, Dietz U, Kyle-Leinhase I, Muysoms F, Asti E, Sironi A, Bonavina L, Rogmark P.

Hernia. 2015 Apr;19 Suppl 1:S139-43. doi: 10.1007/BF03355341. No abstract available.

PMID:
26518791
7.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.

Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De Tursi M, Santoro A, Crinò L, Buttitta F.

J Thorac Oncol. 2015 Oct;10(10):1437-43. doi: 10.1097/JTO.0000000000000643.

8.

Robot-assisted surgery for gastric carcinoma: Five years follow-up and beyond: A single western center experience and long-term oncological outcomes.

Coratti A, Fernandes E, Lombardi A, Di Marino M, Annecchiarico M, Felicioni L, Giulianotti PC.

Eur J Surg Oncol. 2015 Aug;41(8):1106-13. doi: 10.1016/j.ejso.2015.01.014. Epub 2015 Feb 23.

PMID:
25796984
9.

Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer.

Gasparini G, Buttitta F, D'Andrea MR, Tumolo S, Buonadonna A, Pavese I, Cordio S, De Tursi M, Mosconi S, Stumbo L, Felicioni L, Marchetti A.

Neoplasia. 2014 Sep;16(9):751-6. doi: 10.1016/j.neo.2014.08.002.

10.

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.

Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, De Pas T, Santoro A, Chella A, Brandes AA, Venturino P, Cuccurullo F, Crinò L, Buttitta F.

PLoS One. 2014 Aug 19;9(8):e103883. doi: 10.1371/journal.pone.0103883. eCollection 2014.

11.

Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.

Buttitta F, Felicioni L, Del Grammastro M, Filice G, Di Lorito A, Malatesta S, Viola P, Centi I, D'Antuono T, Zappacosta R, Rosini S, Cuccurullo F, Marchetti A.

Clin Cancer Res. 2013 Feb 1;19(3):691-8. doi: 10.1158/1078-0432.CCR-12-1958. Epub 2012 Dec 14.

12.

Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.

Marchetti A, Del Grammastro M, Filice G, Felicioni L, Rossi G, Graziano P, Sartori G, Leone A, Malatesta S, Iacono M, Guetti L, Viola P, Mucilli F, Cuccurullo F, Buttitta F.

PLoS One. 2012;7(7):e42164. doi: 10.1371/journal.pone.0042164. Epub 2012 Jul 27.

13.

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.

Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, Marchetti A, Mottolese M, Cognetti F.

J Thorac Oncol. 2012 Apr;7(4):672-80. doi: 10.1097/JTO.0b013e31824a8bde.

14.

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, Buttitta F, Felicioni L, Migaldi M, Rea F, Di Chiara F, Mengoli MC, Rossi G.

Ann Oncol. 2012 Sep;23(9):2409-14. doi: 10.1093/annonc/mdr626. Epub 2012 Feb 21.

PMID:
22357254
15.

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, Viola P, Pullara C, Mucilli F, Buttitta F.

J Clin Oncol. 2011 Sep 10;29(26):3574-9. doi: 10.1200/JCO.2011.35.9638. Epub 2011 Aug 8.

PMID:
21825258
16.

A unique microRNA signature associated with plaque instability in humans.

Cipollone F, Felicioni L, Sarzani R, Ucchino S, Spigonardo F, Mandolini C, Malatesta S, Bucci M, Mammarella C, Santovito D, de Lutiis F, Marchetti A, Mezzetti A, Buttitta F.

Stroke. 2011 Sep;42(9):2556-63. doi: 10.1161/STROKEAHA.110.597575. Epub 2011 Aug 4.

PMID:
21817153
17.

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M.

Clin Cancer Res. 2011 Jul 15;17(14):4901-14. doi: 10.1158/1078-0432.CCR-10-3137. Epub 2011 Jun 1.

18.

Robot-assisted treatment of splenic artery aneurysms.

Giulianotti PC, Buchs NC, Coratti A, Sbrana F, Lombardi A, Felicioni L, Bianco FM, Addeo P.

Ann Vasc Surg. 2011 Apr;25(3):377-83. doi: 10.1016/j.avsg.2010.09.014. Epub 2011 Jan 28.

PMID:
21276711
19.

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S, Cognetti F, Buttitta F.

Neoplasia. 2009 Oct;11(10):1084-92.

20.

Mutational profile of GNAQQ209 in human tumors.

Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M, Marchetti A, Bardelli A.

PLoS One. 2009 Aug 31;4(8):e6833. doi: 10.1371/journal.pone.0006833.

21.

MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway.

Mancini F, Di Conza G, Pellegrino M, Rinaldo C, Prodosmo A, Giglio S, D'Agnano I, Florenzano F, Felicioni L, Buttitta F, Marchetti A, Sacchi A, Pontecorvi A, Soddu S, Moretti F.

EMBO J. 2009 Jul 8;28(13):1926-39. doi: 10.1038/emboj.2009.154. Epub 2009 Jun 11.

22.

Molecular profiling of the "plexinome" in melanoma and pancreatic cancer.

Balakrishnan A, Penachioni JY, Lamba S, Bleeker FE, Zanon C, Rodolfo M, Vallacchi V, Scarpa A, Felicioni L, Buck M, Marchetti A, Comoglio PM, Bardelli A, Tamagnone L.

Hum Mutat. 2009 Aug;30(8):1167-74. doi: 10.1002/humu.21017.

23.

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M.

J Clin Oncol. 2009 Apr 1;27(10):1667-74. doi: 10.1200/JCO.2008.19.1635. Epub 2009 Mar 2.

24.

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.

Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A.

Hum Mutat. 2009 Jan;30(1):7-11. doi: 10.1002/humu.20937.

PMID:
19117336
25.

AKT1(E17K) in human solid tumours.

Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Grammastro MD, Sciarrotta MG, Zanon C, Marchetti A, Bardelli A.

Oncogene. 2008 Sep 18;27(42):5648-50. doi: 10.1038/onc.2008.170. Epub 2008 May 26.

PMID:
18504432
26.

Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung.

Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, Malatesta S, Chella A, Barassi F, Mucilli F, Camplese P, D'Antuono T, Sacco R, Buttitta F.

Hum Mutat. 2008 May;29(5):609-16. doi: 10.1002/humu.20707.

PMID:
18293376
27.

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.

Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, Buttitta F, Felicioni L, Nicassio F, Di Fiore PP.

J Clin Invest. 2007 Nov;117(11):3436-44.

28.

Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.

Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A.

Clin Cancer Res. 2007 Oct 15;13(20):6064-9.

29.

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.

Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, Paolizzi D, Lattanzio G, Salvatore S, Camplese PP, Rosini S, Iarussi T, Mucilli F, Sacco R, Mezzetti A, Marchetti A.

Int J Cancer. 2006 Dec 1;119(11):2586-91.

30.

Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation.

Bon G, Folgiero V, Bossi G, Felicioni L, Marchetti A, Sacchi A, Falcioni R.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3280-7.

31.

Assessing EGFR mutations.

Marchetti A, Felicioni L, Buttitta F.

N Engl J Med. 2006 Feb 2;354(5):526-8; author reply 526-8. No abstract available.

PMID:
16452569
32.

PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.

Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A.

J Pathol. 2006 Feb;208(3):350-5.

PMID:
16353168
33.

Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.

Giglio S, Mancini F, Gentiletti F, Sparaco G, Felicioni L, Barassi F, Martella C, Prodosmo A, Iacovelli S, Buttitta F, Farsetti A, Soddu S, Marchetti A, Sacchi A, Pontecorvi A, Moretti F.

Cancer Res. 2005 Nov 1;65(21):9687-94.

34.

Int6 expression can predict survival in early-stage non-small cell lung cancer patients.

Buttitta F, Martella C, Barassi F, Felicioni L, Salvatore S, Rosini S, D'Antuono T, Chella A, Mucilli F, Sacco R, Mezzetti A, Cuccurullo F, Callahan R, Marchetti A.

Clin Cancer Res. 2005 May 1;11(9):3198-204.

35.

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F.

J Clin Oncol. 2005 Feb 1;23(4):857-65.

PMID:
15681531
36.

Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma.

Buttitta F, Pellegrini C, Marchetti A, Gadducci A, Cosio S, Felicioni L, Barassi F, Salvatore S, Martella C, Coggi G, Bosari S.

J Clin Oncol. 2003 Apr 1;21(7):1320-5.

PMID:
12663721
37.

Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation.

Marchetti A, Pellegrini C, Buttitta F, Falleni M, Romagnoli S, Felicioni L, Barassi F, Salvatore S, Chella A, Angeletti CA, Roncalli M, Coggi G, Bosari S.

Lab Invest. 2002 Jun;82(6):729-36.

PMID:
12065683
38.

mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients.

Marchetti A, Buttitta F, Bertacca G, Zavaglia K, Bevilacqua G, Angelucci D, Viacava P, Naccarato A, Bonadio A, Barassi F, Felicioni L, Salvatore S, Mucilli F.

J Pathol. 2001 Sep;195(2):186-90.

PMID:
11592097
39.

[Tubercular enteral fistulas].

Ceccherini E, Sereni P, Felicioni L, Testi W, Mancini S.

Minerva Chir. 1989 Apr 30;44(8):1293-5. Italian.

PMID:
2761729

Supplemental Content

Loading ...
Support Center